AstraZeneca and Gilead Compete for Leadership in Triple-Negative Breast Cancer Treatments
TL;DR
Major pharmaceutical companies Gilead, AstraZeneca, and Roche reported promising new study results for cancer treatments, particularly in breast cancer, leading to stock price increases for Gilead and AstraZeneca, while Roche's shares declined slightly. The studies highlight advancements in drug efficacy and potential growth in the cancer drug market, with implications for future sales and industry competition.
- Gilead, AstraZeneca, and Roche Data Signal New Growth in Cancer Drug Market TipRanks
- ESMO 2025 – Datroway and Trodelvy face off in triple-negative breast | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
- At ESMO, AstraZeneca and Gilead square off in triple-negative breast cancer statnews.com
- Drug groups unveil advances in treating most difficult breast cancers Financial Times
- ESMO: AZ, Daiichi's Datroway outshines Gilead's Trodelvy in first global TROP2 showdown Fierce Pharma
Want the full story? Read the original reporting
Read on TipRanks